63 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
16 May 24
Current report (foreign)
2:21pm
the Company settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, the Company licenses specified … into a settlement and license agreement with Alnylam, pursuant to which the Company settled outstanding patent litigation with Alnylam related to its RNAi
6-K
EX-99.1
SLN
Silence Therapeutics Plc
13 Mar 24
Current report (foreign)
7:10am
of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s cash runway and forecast
6-K
EX-99.1
SLN
Silence Therapeutics Plc
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
6-K
EX-99.2
SLN
Silence Therapeutics Plc
6 Feb 24
Securities Purchase Agreement
12:00am
or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees … in respect of such claim or litigation.
6.4. Contribution. If for any reason the indemnification provided for in the preceding Sections 6.1 and 6.2
6-K
EX-99.1
04pm8 4dn
6 Feb 24
Securities Purchase Agreement
12:00am
6-K
EX-99.1
8reufsj5uqhd9kuv0
1 Dec 23
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
7:00am
6-K
EX-99.1
g3x3lhsr92 fa8t5k
14 Nov 23
Current report (foreign)
12:00am
6-K
EX-99.1
0703ignhcm0k2sz
1 Nov 23
Current report (foreign)
7:00am
6-K/A
EX-99.1
j4nhw4
29 Aug 23
Current report (foreign) (amended)
4:01pm
6-K
EX-99.1
qukz6
16 Aug 23
Current report (foreign)
7:00am
6-K
EX-99.1
2cj y5j54gp
11 Jul 23
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
7:00am
6-K
EX-99.1
4tjd0 f39
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
x83velo9fp3n
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
gvhywq0nbvvsh 828j8j
1 May 23
Current report (foreign)
7:31am
6-K
EX-99.1
ccgcf0l8r f3ntq42u
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
i8jtj
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
EX-99.1
mmeya4d weardmx2548
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-1.1
4xi5tl4d
16 Aug 22
Current report (foreign)
4:43pm
424B5
iqnlcserpg 70717zyq
12 Aug 22
Prospectus supplement for primary offering
1:32pm